Allena Pharmaceuticals, Inc. (ALNAQ) Research

Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on unearthing, developing, and marketing oral enzyme therapies. These treatments are devised to assist patients in the United States afflicted by uncommon and serious metabolic as well as renal conditions. Central to its pipeline is ALLN-346, an innovative enzyme designed to degrade urate, targeting hyperuricemia and gout in individuals with advanced chronic kidney disease. The company, which commenced operations in 2011 and has its main office in Newton, Massachusetts, made headlines on September 2, 2022, by seeking voluntary reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Market snapshot

Symbol
ALNAQ
Price
$0.00
Day change
-99.00%
Market cap
$40.3M
P/E ratio
-0.07x
52-week range
1.0E-6-0.0185
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Primo Nutraceuticals Inc. (BUGVF)
  • Green Hygienics Holdings Inc. (GRYN)
  • IMV Inc. (IMVIQ)
  • Indie Ranch Media, Inc. (INDR)
  • LifeHOUSE Holdings, LLC (LHRP)
  • Photoelectron Corp. (PECN)
  • QMed, Inc. (QMED)
  • ReGen Biologics Inc. (RGBOQ)

Open Allena Pharmaceuticals, Inc. (ALNAQ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.